ホーム>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> AMPK>>YLF-466D

YLF-466D

カタログ番号GC18208

YLF-466D は、血小板凝集を阻害する新開発の AMPK アクチベーターです。

Products are for research use only. Not for human use. We do not sell to patients.

YLF-466D 化学構造

Cas No.: 1273323-67-3

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$177.00
在庫あり
2mg
$115.00
在庫あり
5mg
$187.00
在庫あり
10mg
$299.00
在庫あり
50mg
$958.00
在庫あり
100mg
$1,037.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

YLF-466D is a newly developed AMPK activator, which inhibits platelet aggregation.

The effect of YLF-466D on platelet AMPK and aggregation are examined to test whether YLF-466D can stimulate AMPK in platelets and thereby suppress aggregation. Platelet AMPK is activated by YLF-466D, which is confirmed with activation-dependent phosphorylation at Thr172. Consistent with this result, YLF-466D inhibits platelet aggregation induced by thrombin. Such inhibition is observed in the aggregation elicited by ADP and collagen as well as thrombin, indicating that the antiaggregatory effect of YLF-466D is not platelet-agonist specific but common, regardless of agonist type. All the effects on AMPK and aggregation are concentration-dependent with the highest efficacy at 150 μM. IC50 against thrombin-, ADP- and collagen-induced aggreation are approximately 84, 55 and 87 μM, respectively[1].

References:
[1]. Liu Y, et al. Antiplatelet effect of a newly developed AMP-activated protein kinase activator YLF-466D. Eur J Pharmacol. 2015 Aug 5;760:81-7.

レビュー

Review for YLF-466D

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for YLF-466D

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.